Alimera Announces Scientific Data Highlighting YUTIQ to Be Presented at Upcoming Association for Research in Vision and Ophthalmology and Retina World Congress Conferences
Alimera Announces Scientific Data Highlighting YUTIQ to Be Presented at Upcoming Association for Research in Vision and Ophthalmology and Retina World Congress Conferences
ATLANTA, May 07, 2024 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) ("Alimera"), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, announced today it will have three scientific abstracts at two upcoming ophthalmic congresses including the Association for Research in Vision and Ophthalmology (ARVO) conference, scheduled in Seattle, WA. from May 5 - 9 and Retina World Congress (RWC) scheduled in Fort Lauderdale, FL. from May 9 - 13.
亞特蘭大，2024年5月7日（GLOBE NEWSWIRE）——全球製藥公司Alimera Sciences, Inc.（納斯達克股票代碼：ALIM）（“Alimera”）是一家全球製藥公司，其使命是爲關注視網膜健康和更長時間保持更好視力的患者、醫生和合作夥伴提供無價的服務。該公司今天宣佈，將在包括視覺與眼科研究協會（ARVO）會議在內的兩次眼科大會上發表三份科學摘要，定於5月5日至9日在華盛頓州西雅圖舉行，視網膜世界大會（RWC）定於5月9日至13日在佛羅里達州勞德代爾堡舉行。
ARVO Key Abstracts:
ARVO 關鍵摘要：
- Tue, May 07 8:30am - 10:15am PT; Tedi Begaj, MD; Lisa Faia, MD
CALM: 24-Month Safety Outcomes From a Real-World Registry Study of Patients with Chronic Non-infectious Uveitis Affecting the Posterior Segment Treated with the 0.18 mg Fluocinolone Acetonide Intravitreal Implant (Poster A0170)
- 太平洋時間 5 月 7 日星期二上午 8:30 至上午 10:15；醫學博士 Tedi Begaj；醫學博士 Lisa Faia
CALM：一項針對使用 0.18 mg 氟西諾龍丙酮玻璃體內植入治療的影響後段的慢性非感染性葡萄膜炎患者的真實世界註冊研究得出的 24 個月安全結果（海報 A0170）
- Thu, May 09 2:30pm - 2:45pm PT; Phoebe Lin, MD
CALM: 24-Month Retinal Thickness Outcomes From a Real-World Registry Study of Patients with Chronic Non-infectious Uveitis Affecting the Posterior Segment Treated with the 0.18 mg Fluocinolone Acetonide Intravitreal Implant (Abstract #6454)
- 太平洋時間 5 月 9 日星期四下午 2:30 至下午 2:45；醫學博士菲比·林
CALM：一項針對使用 0.18 mg 氟西諾龍丙酮玻璃體內植入治療的影響後段的慢性非感染性葡萄膜炎患者的真實世界註冊研究得出的 24 個月視網膜厚度結果（摘要 #6454）
RWC Key Abstract:
RWC 密鑰摘要：
- Poster-on-demand, Michael Singer, MD
36-month Outcomes Following Treatment of Chronic Non-infectious Uveitis Affecting the Posterior Segment with the 0.18 mg Fluocinolone Acetonide Intravitreal Implant: a CALM Registry Analysis
- 海報點播，邁克爾·辛格，醫學博士
使用 0.18 mg 氟西諾龍丙酮玻璃體內植入治療影響後段的慢性非感染性葡萄膜炎後 36 個月的療效：CALM 註冊分析
About YUTIQ
YUTIQ is a sustained release fluocinolone acetonide intravitreal implant injected into the back of the eye using CONTINUOUS MICRODOSING technology, which is designed to release sub-microgram levels of fluocinolone acetonide, a corticosteroid, for up to 36 months, to reduce the recurrence of disease and enable patients to maintain vision longer with fewer injections. YUTIQ helps provide CONTINUOUS CALM by reducing recurrence of inflammation in the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. For more information, please visit
關於 YUTIQ
YUTIQ 是一種持續釋放的氟西諾龍丙酮玻璃體內植入物，使用連續微劑量技術注射到眼後，該技術旨在釋放亞微克水平的氟西諾龍丙酮（一種皮質類固醇），持續時間長達 36 個月，以減少疾病復發，使患者能夠以更少的注射次數維持更長的視力。在治療影響眼後段的慢性非感染性葡萄膜炎時，YUTIQ 通過減少炎症復發來幫助提供持續的鎮靜。欲了解更多信息，請訪問
About Alimera Sciences, Inc.
Alimera Sciences is a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer. For more information, please visit .
關於 Alimera Sciences, Inc.
Alimera Sciences是一家全球製藥公司，其使命是爲關注視網膜健康和更長時間保持更好視力的患者、醫生和合作夥伴提供無價的服務。欲了解更多信息，請訪問。
|
For press inquiries: Cassy Dump for Alimera Sciences 619-971-1887 cassy@heyshine.com |
For investor inquiries: Scott Gordon for Alimera Sciences scottg@coreir.com |
| 媒體垂詢： Cassy Dump 適用於 Alimera 科學 619-971-1887 cassy@heyshine.com |
投資者垂詢： 斯科特·戈登 爲阿里默拉科學公司提供 scottg@coreir.com |